We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Takeda Acquires U.S. Biologics Manufacturing Facility

Rectangle Image
News

Takeda Acquires U.S. Biologics Manufacturing Facility

Read time:
 

Takeda intends to use the facility primarily for the manufacture of Entyvio®( vedolizumab) and other biologic products, allowing the company to maximize global efficiencies and further enhance the product’s supply chain flexibility.

“Takeda’s focus is providing patients access to quality therapies,” said Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda. “Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”

The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.

Advertisement